M1223 Toll Like Receptors 8 and 9 mRNA Expression are Up-Regulated in Active Ulcerative Colitis and Correlated With Disease Activity

2010 ◽  
Vol 138 (5) ◽  
pp. S-358
Author(s):  
Jesus K. Yamamoto-Furusho ◽  
Fausto Sanchez-Muñoz ◽  
Misael Uribe-Esquivel
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Mrna Expression ◽  
Active Ulcerative Colitis ◽  
Toll Like Receptors

Serpin B1 protects colonic epithelial cell via blockage of neutrophil elastase activity and its expression is enhanced in patients with ulcerative colitis

2012 ◽  
Vol 302 (10) ◽  
pp. G1163-G1170 ◽  
Author(s):  
Kazuhiko Uchiyama ◽  
Yuji Naito ◽  
Tomohisa Takagi ◽  
Katsura Mizushima ◽  
Yasuko Hirai ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Mrna Expression ◽  
Real Time ◽  
Neutrophil Elastase ◽  
Colonic Mucosa ◽  
Clinical Samples ◽  
Active Ulcerative Colitis ◽  
Inflammatory Infiltration ◽  
Serpin B1

Serpin B1 is a monocyte neutrophil elastase (NE) inhibitor and is one of the most efficient inhibitors of NE. In the present study, we investigated the role of serpin B1 in the pathogenesis of ulcerative colitis by using clinical samples and an experimental model. The colonic expression of serpin B1 was determined by real-time polymerase chain reaction (PCR), Western blot analysis, and immunohistological studies in both normal and inflamed mucosa from patients with ulcerative colitis. Serpin B1 mRNA expression was determined by real-time PCR in the mouse dextran sodium sulfate (DSS)-induced colitis model. Young adult mouse colonic epithelial (YAMC) cells were used to determine the role of serpin B1. Serpin B1 gene transfected YAMC cells were treated with H2O2 to measure cell viability. The expression of NE was determined in YAMC cells treated with H2O2. NE-silenced YAMC cells were also treated with H2O2 and then measured for viability. Upregulated expression of serpin B1 in colonic mucosa was confirmed from patients with active ulcerative colitis. Immunohistochemical studies showed that serpin B1 expression was localized not only in inflammatory infiltration cells but also in epithelial cells. Serpin B1 mRNA expression was also increased in colonic mucosa of mouse DSS-induced colitis. Serpin B1-transfected YAMC cells were resistant against the treatment of H2O2. H2O2 treatment significantly induced NE in YAMC cells, and NE-silenced YAMC cells were also resistant against the treatment of H2O2. These results suggest that serpin B1 may be a novel marker of active ulcerative colitis and may play an important role in the pathogenesis of inflammatory bowel disease.

scholarly journals Obestatin/Ghrelin Ratio as a New Activity Index in Ulcerative Colitis

2019 ◽  
Vol 4 (04) ◽  
Author(s):  
Mohammed Amin Mohammed ◽  
Nesreen Moustafa Omar
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Mrna Expression ◽  
Activity Index ◽  
Strong Relationship ◽  
Serum Levels ◽  
Ghrelin Level ◽  
Mucosal Inflammation ◽  
Predictive Values ◽  
Serum Ghrelin

Background and Aim: Ulcerative colitis (UC) is an immune-mediated systemic inflammatory process that destroys the intestinal mucosa. Ghrelin, an appetite-regulatory hormone, has anti-inflammatory effects including a decrease in circulating cytokines. Some reports demonstrated a strong relationship between the serum ghrelin level and the severity of mucosal inflammation in the gastrointestinal tract. The aim is to investigate serum levels and colonic mucosal mRNA expression of ghrelin, obestatin, and obestatin/ghrelin ratio in patients with UC and to determine their potential as markers for UC disease activity. Patients and Methods: seventy-five outpatients with UC and 45 age- and sex-matched healthy volunteers were enrolled in this study after written conscious consent and approval by the Institutional Review Board of Mansoura University. UC was diagnosed by conventional clinical, radiological, endoscopic, and histopathological criteria. Serum ghrelin, obestatin levels, and their mucosal mRNA expression were measured by ELISA kits and a real-time quantitative reverse transcriptase polymerase chain reaction according to the manufacturer’s protocols. Results: Serum levels and mucosal mRNA expression of ghrelin were significantly higher in patients with active UC than patients in remission p˂0.0001). Obestatin/ghrelin ratio was significantly lower in patients with active UC (0.26±0.08) than those in remission (0.523±0.16; p˂0.0001). Obestatin/ghrelin ratio was negatively and significantly correlated with inflammation and endoscopic scores, colitis activity index, serum ghrelin level, and its mucosal mRNA expression (p˂0.05). Conclusion: obestatin/ghrelin ratio might be a reliable surrogate non-invasive marker of disease activity in UC with significantly high sensitivity, specificity, predictive values, and diagnostic accuracy.

scholarly journals Serum Beta 2-Microglobulin as a Biomarker of Activity in Ulcerative Colitis

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E H Nashaat ◽  
M M Mohamed ◽  
T M Aziz ◽  
M W Nakhla
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Disease Severity ◽  
Inactive Disease ◽  
Control Group ◽  
Active Ulcerative Colitis ◽  
Presenting Symptoms ◽  
Non Invasive ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Abstract Background ulcerative colitis (UC) is a chronic, idiopathic, inflammatory bowel disease that causes inflammation and ulcers in the innermost layers of the large intestine (colon) and rectum. Assessment of intestinal inflammation in UC is crucial and still remains a difficult challenge for the clinician. Although endoscopic modalities with biopsy sampling seem to be the most reliable method for estimating disease severity, they are invasive and costly. Apart from endoscopic interventions, disease severity can be assessed using both laboratory studies and non-invasive imaging tests. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cells (WBCs), acid glycoprotein, platelet count and albumin are in common use but have only modest accuracy in reflecting UC disease activity. Therefore, adjunctive use of additional serum markers that will be more sensitive and specific for determination of disease activity and achieving diagnostic accuracy is strongly needed in daily clinical practice. Aim of the Work to investigate the diagnostic utility of beta 2 microglobulin (B2-M) levels and analyze this correlation with the activity of ulcerative colitis disease. Patients and Methods a case control study that was conducted at the Gastroenterology Clinic, Internal Medicine Department, Ain Shams University during the period of January to July 2018. 60 patients were recruited for the study. They were divided as follows; Group “A”: 40 patients newly diagnosed as ulcerative colitis based on colonoscopy and biopsy, subdivided as follows; 20 patients with active ulcerative colitis and 20 patients with inactive ulcerative colitis. Group “B”: 20 healthy individuals free from any systemic diseases serving as a control group. Results in this study, the serum levels of serum B2-microglobulins were highest in patients with active ulcerative colitis compared to those with inactive ulcerative colitis and the control groups. Also B2-microglobulins values become higher with higher number of presenting symptoms and endoscopic activity, which becomes higher in severe disease. Conclusion our results revealed that serum B2-microglobulin was simple and non-invasive marker that could be helpful for differentiating active UC from inactive disease. Moreover, it was more helpful when used together with serum laboratory inflammatory indices (ESR and CRP).

scholarly journals Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents

2019 ◽  
Vol 8 (12) ◽  
pp. 2109 ◽  
Author(s):  
Eriko Yasutomi ◽  
Sakiko Hiraoka ◽  
Shumpei Yamamoto ◽  
Shohei Oka ◽  
Mami Hirai ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Practice ◽  
Disease Activity ◽  
High Dose ◽  
Active Ulcerative Colitis ◽  
Dose Treatment ◽  
High Dose Treatment ◽  
Oral Mesalazine

Background and aim: Oral mesalazine and sulfasalazine (SASP) are key drugs for treating ulcerative colitis (UC). The efficacy of switching from one of the several mesalazine formulations to another is largely unknown. This study assessed the efficacy of switching among three types of mesalazine formulation and SASP for UC therapy. Methods: UC patients receiving high-dose mesalazine/SASP who switched to other formulations due to disease activity were considered eligible. Efficacy was evaluated 2, 6, and 12 months after switching. Results: A total of 106 switches in 88 UC patients were analyzed. The efficacy at 2 months after switching was observed in 23/39 (59%) cases from any mesalazine formulation to SASP, in 18/55 (33%) cases from one mesalazine to another, and in 2/12 (17%) cases from SASP to any mesalazine formulation. Nine of 43 effective cases showed inefficacy or became intolerant post-switching. Delayed efficacy more than two months after switching was observed in four cases. Steroid-free remission was achieved in 42/106 (39%) cases—within 100 days in 35 of these cases (83%). Conclusions: Switching from mesalazine to SASP was effective in more than half of cases. The efficacy of switching between mesalazine formulations was lower but may be worth attempting in clinical practice from a safety perspective.

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Carla Marinelli ◽  
Fabiana Zingone ◽  
Maria Giovanna Lupo ◽  
Raffaella Marin ◽  
Renata D’Incà ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Serum Levels ◽  
Active Ulcerative Colitis ◽  
Potential Biomarker

scholarly journals The Association of Diet and Physical Activity with Disease Activity in Ulcerative Colitis (P18-091-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Ilse Schilderinck ◽  
Carlijn Lamers ◽  
Nicole de Roos
Keyword(s):  
Physical Activity ◽  
Ulcerative Colitis ◽  
Disease Activity ◽  
Nutrient Intake ◽  
Activity Index ◽  
Activity Score ◽  
Moderate Activity ◽  
Active Ulcerative Colitis ◽  
Online Questionnaire ◽  
Diet And Physical Activity

Abstract Objectives Data on diet and physical activity in ulcerative colitis patients are scarce and frequently mixed with data of patients with Crohn's disease. Therefore, the objective of this study is to investigate habitual diet and physical activity of ulcerative colitis patients and to determine whether there is an association with disease activity. Methods In this cross-sectional study, data of 172 subjects were collected via an online questionnaire that consisted of several validated questionnaires: the Patient Simple Clinical Colitis Activity Index (P-SCCAI) to assess disease activity, a Food Frequency Questionnaire (FFQ) to assess habitual nutrient intake and the Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH) to assess habitual physical activity. Nutrient intake was used to calculate the Adjusted Dietary Inflammatory Index (ADII). Physical activity data were used to calculate intensity levels (light, moderate or vigorous intensity) and duration of activity (min/week). These were used combined with age to calculate activity scores. Correlations between the ADII and physical activity with disease activity were investigated. Results The ADII ranged from −5.45 to 3.79 with a mean (±SD) of 0.00 (±1.55). The mean ADII was anti-inflammatory (−0.08) in subjects in remission, while it was pro-inflammatory in subjects with mild and moderately active ulcerative colitis (0.06 and 0.42, respectively), although the correlation between ADII and disease activity was not significant. With regard to physical activity, most minutes per week were spent on light to moderate activity at work or school (median [IQR] of 1375 [825]). The activity with the highest activity score was heavy activity at work or school (median [IQR] of 2160 [6480]). Subjects mostly performed activities of light intensity (median [IQR] of 840 [1575]). No significant differences in intensity levels, duration and activity score between subjects in remission and mild or moderately active ulcerative colitis were found. Also, no correlations were found between intensity levels, duration and activity score with disease activity. Conclusions We found no associations of diet and physical activity with disease activity in patients with ulcerative colitis. Funding Sources N.A.

scholarly journals AB0016 ASSOCIATION OF PTPN22 GENETIC VARIANTS WITH DISEASE SUSCEPTIBILITY AND CLINICAL VARIABLES IN PRIMARY SJÖGREN SYNDROME

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1311.1-1312
Author(s):  
P. A. Menchaca Tapia ◽  
E. Oregón Romero ◽  
D. C. Salazar Camarena ◽  
M. Marin Rosales ◽  
J. F. Muñoz Valle ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Mrna Expression ◽  
Genetic Variants ◽  
Sjögren Syndrome ◽  
Colorectal Disease ◽  
Sjogren Syndrome ◽  
Western Mexico ◽  
Link Type ◽  
Development Risk

Background:Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by dysfunction of exocrine glands secondary to lymphocytic infiltration. Lymphoid tyrosine phosphatase (LYP) regulates T and B lymphocyte activation.PTPN22gene encodes LYP; multiple polymorphic variants have been described as genetic risk factor of autoimmune diseases.Objectives:The aim was to analyze thePTPN22rs2488457G>C, rs33996649G>A, and rs2476601C>T genetic variants relationship with the development risk of pSS in the western Mexico population.Methods:One hundred and eighty healthy subjects (HS) and 150 pSS patients, classified according to EULAR 2016 criteria, were included. The genetic variants and mRNA expression were determined through PCR-RFLP and qPCR assays.Results:The frequency of heterozygote rs33996649GA genotype was higher in pSS patients than HS [OR=3.143 (1–10.234), p=0.046], and also, rs33996649GA genotype was associated with high SSDAI score (p=0.01). The pSS patients showed 44-fold more mRNA expression in comparison with HS (p=0.002), and mRNA expression correlates with SSDAI (r2=0.512, p=0.006).Conclusion:The rs33996649G>A genetic variant of thePTPN22gene is associated with increased development risk of pSS in the western Mexican population. The expression mRNA correlates with disease activity in pSS.References:[1]Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Ramos-Casals, M. (2016). Sjögren syndrome.Nature Reviews Disease Primers, 2(July), 1–20.https://doi.org/10.1038/nrdp.2016.47[2]Stanford, S. M., & Bottini, N. (2014). PTPN22: The archetypal non-HLA autoimmunity gene.Nature Reviews Rheumatology,10(10), 602–611.https://doi.org/10.1038/nrrheum.2014.109[3]Chen, Z., Zhang, H., Xia, B., Wang, P., Jiang, T., Song, M., & Wu, J. (2013). Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.International Journal of Colorectal Disease,28(10), 1351–1358.https://doi.org/10.1007/s00384-013-1671-3[4]Machado-Contreras, J. R., Muñoz-Valle, J. F., Cruz, A., Salazar-Camarena, D. C., Marín- Rosales, M., & Palafox-Sánchez, C. A. (2016b). Distribution of PTPN22 polymorphismsin SLE from western Mexico: correlation with mRNA expression and disease activity.Clinical and Experimental Medicine,16(3), 399–406.https://doi.org/10.1007/s10238-015-0359-0Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document